-Bloomberg
SVB Leerink Maintains Outperform on InflaRx, Lowers Price Target to $4
SVB Leerink analyst Joseph Schwartz maintains InflaRx (NASDAQ:IFRX) with a Outperform and lowers the price target from $6 to $4.
Related Posts
Morgan Stanley Upgrades Prelude Therapeutics to Overweight, Lowers Price Target to $35
Morgan Stanley upgrades Prelude Therapeutics (NASDAQ:PRLD) from Equal-Weight to Overweight and lowers the price target from $60 to $35.
What Does BrightView Holdings Debt Look Like?
Shares of BrightView Holdings (NYSE:BV) decreased by 8.5% on Monday. Before we understand the importance of debt, let us look at how much debt BrightView Holdings has.
Canaccord Genuity Initiates Coverage On Qualys with Buy Rating, Announces Price Target of $180
Canaccord Genuity analyst Michael Walkley initiates coverage on Qualys (NASDAQ:QLYS) with a Buy rating and announces Price Target of $180.